Another clinical case of an EML4-ALK+ positive NSCLC patient reported the co-existence of EGFR mutation and a response to both EGFR and ALK-tyrosine kinase inhibitors [23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.